These metabolites could have potential as lead compounds for treating metabolic syndrome, obesity, and diabetes via the inhibition of various enzymes, such as HSD, PTP1BI, α-GI, G6Pase, and DGAT. Here, G6PC1 is linked to diabetes mellitus.